Cytokinetics’ Phase II HF Data: Traders Skeptical, Amgen Not

Cytokinetics Inc. and licensor Amgen Inc. will wait until a Phase II study in chronic heart failure with orally given omecamtiv mecarbil generates data to decide the fate of the compound, which fizzled in a Phase II trial testing the intravenous form of the cardiac myosin activator against acute heart failure.